The Gross Margin of Compass Pathways PLC (CMPS) is
7775.20%.
Gross Margin represents the percentage of revenue that exceeds the cost of goods sold. It reflects a company's efficiency in producing and selling its products.
| Date |
Value |
| 2025-12-31 |
7775.20%
|
| Ticker |
Name |
Value |
|
IMCR
|
Immunocore Holdings PLC
|
98.73%
|
|
ADAP
|
Adaptimmune Therapeutics PLC
|
99.96%
|
|
ITOS
|
iTeos Therapeutics Inc
|
7775.20%
|
|
OXB.L
|
Oxford Biomedica PLC
|
39.10%
|
|
SLN.L
|
Silence Therapeutics PLC
|
3133.78%
|
|
CCCC
|
C4 Therapeutics, Inc.
|
7775.20%
|
|
KNTE
|
Kinnate Biopharma Inc
|
7775.20%
|
|
KRYS
|
Krystal Biotech, Inc.
|
94.08%
|
|
ATRA
|
Atara Biotherapeutics, Inc.
|
82.44%
|
|
KROS
|
Keros Therapeutics, Inc.
|
7775.20%
|
|
NKTX
|
Nkarta, Inc.
|
7775.20%
|
|
QURE
|
uniQure N.V.
|
89.53%
|
|
REPL
|
Replimune Group, Inc.
|
7775.20%
|
|
STOK
|
Stoke Therapeutics, Inc.
|
7775.20%
|
|
STTK
|
Shattuck Labs Inc
|
7775.20%
|
|
PCVX
|
Vaxcyte, Inc.
|
7775.20%
|
|
ABC.L
|
Abcam PLC
|
71.12%
|
|
ANNX
|
Annexon, Inc.
|
7775.20%
|
|
ARQT
|
Arcutis Biotherapeutics, Inc.
|
90.24%
|
|
BCYC
|
Bicycle Therapeutics PLC
|
7775.20%
|
|
FDMT
|
4D Molecular Therapeutics Inc
|
7775.20%
|
|
GNS.L
|
Genus PLC
|
39.14%
|
|
NWBO
|
Northwest Biotherapeutics Inc
|
100.00%
|
|
RYTM
|
Rhythm Pharmaceuticals, Inc.
|
89.73%
|
|
KNSA
|
Kiniksa Pharmaceuticals International, PLC
|
88.54%
|
|
KRON
|
Kronos Bio LLC
|
7775.20%
|
|
OCGN
|
Ocugen, Inc.
|
7775.20%
|
|
PRAX
|
Praxis Precision Medicines, Inc.
|
7775.20%
|
|
CNTA
|
Centessa Pharmaceuticals Limited
|
7775.20%
|
|
CYDY
|
Cytodyn Inc
|
-27547.74%
|
|
IMVT
|
Immunovant, Inc.
|
7775.20%
|
|
MYOV
|
Myovant Sciences Ltd
|
77.68%
|
|
VBIV
|
VBI Vaccines Inc
|
-44.06%
|
|
YMAB
|
Y-mAbs Therapeutics Inc
|
82.89%
|
|
ZYME
|
Zymeworks Inc.
|
7775.20%
|